Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies.
Yong, Shin Jie, Liu, Shiliang · Reviews in medical virology · 2022 · DOI
Quick Summary
This review examines long COVID (persistent symptoms lasting months after COVID-19 infection) and proposes that it comes in six different subtypes, one of which is ME/CFS-like illness. The authors describe the symptoms and potential treatments for each subtype, helping doctors and patients better understand which type of long COVID a person might have. This framework could help lead to more targeted treatments since different subtypes may need different approaches.
Why It Matters
This subtyping framework is important because ME/CFS is explicitly recognized as one distinct form of long COVID with potentially different underlying mechanisms and treatment approaches than other long COVID presentations. For ME/CFS patients and researchers, this validates the disease as a recognizable post-viral syndrome while emphasizing the need for subtype-specific research and treatment strategies rather than one-size-fits-all approaches.
Observed Findings
Six distinct clinical subtypes of post-COVID-19 syndrome can be characterized based on symptom patterns and affected organ systems from published literature.
ME/CFS-like presentations in long COVID are characterized by fatigue, post-exertional malaise, and cognitive impairment lasting 3+ months post-infection.
Common long COVID symptoms include fatigue, dyspnea, and cognitive impairments across multiple subtypes.
Different subtypes have distinct symptom patterns and organ system involvement requiring potentially different therapeutic approaches.
10-30% or more of COVID-19 survivors may develop long COVID according to the literature reviewed.
Inferred Conclusions
The heterogeneous presentation of post-COVID-19 syndrome suggests multiple distinct pathophysiological subtypes rather than a single disease entity.
ME/CFS-type illness represents a recognizable and important subtype of long COVID with specific symptoms and potential treatments.
Subtype-based classification could improve clinical clarity and guide development of targeted therapeutic interventions.
Multi-organ involvement is a significant feature across several long COVID subtypes.
Remaining Questions
What is the actual prevalence of each proposed subtype among long COVID patients?
What This Study Does Not Prove
This review does not establish the prevalence of each subtype among long COVID patients, nor does it prove that these six categories are biologically distinct entities. The authors do not present new clinical trial data proving which interventions actually work for each subtype—they only propose potential therapies based on existing literature. The study does not establish causation of the proposed mechanisms.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →